📣 VC round data is live. Check it out!

Yixintang Pharmaceutical Valuation Multiples

Discover revenue and EBITDA valuation multiples for Yixintang Pharmaceutical and similar public comparables like Medplus Health Services, Aldawaa Medical Services, Redcare Pharmacy, Anhui Huaren Health and more.

Yixintang Pharmaceutical Overview

About Yixintang Pharmaceutical

Yixintang Pharmaceutical Group Co Ltd is a China-based company engages in the operation of pharmaceutical retail chains and wholesale businesses. Its products include traditional Chinese medicine, Western medicine, and medical equipment.


Founded

2000

HQ

China

Employees

N/A

Website

hx8886.com

Sectors

Financials (LTM)

Revenue: $3B
EBITDA: $130M

EV

$1B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Yixintang Pharmaceutical Financials

Yixintang Pharmaceutical reported last 12-month revenue of $3B and EBITDA of $130M.

In the same LTM period, Yixintang Pharmaceutical generated $838M in gross profit, $130M in EBITDA, and $54M in net income.

Revenue (LTM)


Yixintang Pharmaceutical P&L

In the most recent fiscal year, Yixintang Pharmaceutical reported revenue of $3B and EBITDA of $262M.

Yixintang Pharmaceutical is profitable as of last fiscal year, with gross margin of 33%, EBITDA margin of 10%, and net margin of 2%.

See analyst estimates for Yixintang Pharmaceutical
LTMLast FY202320242025202620272028
Revenue$3B$3B$3B$3B$3B
Gross Profit$838M$828M$840M$838M$828M
Gross Margin33%33%33%32%33%
EBITDA$130M$262M$292M$236M$262M
EBITDA Margin5%10%11%9%10%
EBIT Margin4%4%6%3%4%
Net Profit$54M$39M$80M$17M$39M
Net Margin2%2%3%1%2%

Financial data powered by Morningstar, Inc.

Yixintang Pharmaceutical Stock Performance

Yixintang Pharmaceutical has current market cap of $1B, and enterprise value of $1B.

Market Cap Evolution


Yixintang Pharmaceutical's stock price is $1.86.

Yixintang Pharmaceutical share price increased by 0.1% in the last 30 days, and decreased by 24.2% in the last year.

Yixintang Pharmaceutical has an EPS (earnings per share) of $0.07.

See more trading valuation data for Yixintang Pharmaceutical
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1B$1B0.0%0.1%-6.7%-24.2%$0.07

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Yixintang Pharmaceutical Valuation Multiples

Yixintang Pharmaceutical trades at 0.4x EV/Revenue multiple, and 7.9x EV/EBITDA.

See NTM and 2027E valuation multiples for Yixintang Pharmaceutical

EV / Revenue (LTM)


Yixintang Pharmaceutical Financial Valuation Multiples

As of May 4, 2026, Yixintang Pharmaceutical has market cap of $1B and EV of $1B.

Yixintang Pharmaceutical has a P/E ratio of 20.3x.

LTMLast FY202320242025202620272028
EV/Revenue0.4x0.4x0.4x0.4x0.4x
EV/EBITDA7.9x3.9x3.5x4.4x3.9x
EV/EBIT9.8x9.5x6.7x12.4x9.5x
EV/Gross Profit1.2x1.2x1.2x1.2x1.2x
P/E20.3x28.2x13.5x65.1x28.2x
EV/FCF5.1x5.2x3.8x4.8x5.2x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Yixintang Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Yixintang Pharmaceutical Margins & Growth Rates

Yixintang Pharmaceutical grew revenue by 5% but EBITDA decreased by 49% in the last fiscal year.

In the most recent fiscal year, Yixintang Pharmaceutical reported gross margin of 33%, EBITDA margin of 10%, and net margin of 2%.

See estimated margins and future growth rates for Yixintang Pharmaceutical

Yixintang Pharmaceutical Margins

Last FY202420252026202720282029
Gross Margin33%32%33%32%
EBITDA Margin10%9%10%5%
EBIT Margin4%3%4%5%
Net Margin2%1%2%3%
FCF Margin8%8%8%8%

Yixintang Pharmaceutical Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth5%4%(4%)5%
Gross Profit Growth4%(0%)(1%)4%
EBITDA Growth(49%)(19%)11%(49%)
EBIT Growth28%(46%)31%28%
Net Profit Growth115%(79%)131%115%
FCF Growth7%(21%)(8%)7%

Data powered by FactSet, Inc. and Morningstar, Inc.

Yixintang Pharmaceutical Operational KPIs

Yixintang Pharmaceutical's Rule of 40 is 10% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Yixintang Pharmaceutical's Rule of X is 17% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Yixintang Pharmaceutical
LTMLast FY202320242025202620272028
Rule of 4010%10%
Bessemer Rule of X18%17%
S&M Expenses to Revenue4%4%4%4%
G&A Expenses to Revenue3%3%0%0%0%
R&D Expenses to Revenue0%0%0%0%
Opex to Revenue28%27%29%28%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Yixintang Pharmaceutical Competitors

Yixintang Pharmaceutical competitors include Medplus Health Services, Aldawaa Medical Services, Redcare Pharmacy, Anhui Huaren Health, AiN Group, Apotea, GoodRx, Pague Menos, Create SD Holdings and Shu Yu Civilian Pharmacy.

Most Yixintang Pharmaceutical public comparables operate across Pharmacies.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Medplus Health Services1.6x1.6x20.4x18.4x
Aldawaa Medical Services0.9x0.9x6.8x6.6x
Redcare Pharmacy0.4x0.4x20.9x17.8x
Anhui Huaren Health1.6x13.3x
AiN Group0.7x0.5x9.7x6.5x
Apotea1.1x1.1x17.7x16.4x
GoodRx1.4x1.5x4.2x4.4x
Pague Menos0.5x0.5x6.4x7.5x

This data is available for Pro users. Sign up to see all Yixintang Pharmaceutical competitors and their valuation data.

Start Free Trial

Yixintang Pharmaceutical M&A Activity

Yixintang Pharmaceutical has acquired 1 company to date.

Last acquisition by Yixintang Pharmaceutical was on May 17th 2022. Yixintang Pharmaceutical acquired Yixintang Simile for $27M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Yixintang Pharmaceutical

Yixintang Simile
Description
HQ CountryChina
HQ City
Deal Date17 May 2022
Valuation$27M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Yixintang Pharmaceutical acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Yixintang Pharmaceutical

When was Yixintang Pharmaceutical founded?Yixintang Pharmaceutical was founded in 2000.
Where is Yixintang Pharmaceutical headquartered?Yixintang Pharmaceutical is headquartered in China.
Is Yixintang Pharmaceutical publicly listed?Yes, Yixintang Pharmaceutical is a public company listed on Shenzhen Stock Exchange.
What is the stock symbol of Yixintang Pharmaceutical?Yixintang Pharmaceutical trades under 002727 ticker.
When did Yixintang Pharmaceutical go public?Yixintang Pharmaceutical went public in 2014.
Who are competitors of Yixintang Pharmaceutical?Yixintang Pharmaceutical main competitors include Medplus Health Services, Aldawaa Medical Services, Redcare Pharmacy, Anhui Huaren Health, AiN Group, Apotea, GoodRx, Pague Menos, Create SD Holdings, Shu Yu Civilian Pharmacy.
What is the current market cap of Yixintang Pharmaceutical?Yixintang Pharmaceutical's current market cap is $1B.
What is the current revenue of Yixintang Pharmaceutical?Yixintang Pharmaceutical's last 12 months revenue is $3B.
What is the current revenue growth of Yixintang Pharmaceutical?Yixintang Pharmaceutical revenue growth (NTM/LTM) is 5%.
What is the current EV/Revenue multiple of Yixintang Pharmaceutical?Current revenue multiple of Yixintang Pharmaceutical is 0.4x.
Is Yixintang Pharmaceutical profitable?Yes, Yixintang Pharmaceutical is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Yixintang Pharmaceutical?Yixintang Pharmaceutical's last 12 months EBITDA is $130M.
What is Yixintang Pharmaceutical's EBITDA margin?Yixintang Pharmaceutical's last 12 months EBITDA margin is 5%.
What is the current EV/EBITDA multiple of Yixintang Pharmaceutical?Current EBITDA multiple of Yixintang Pharmaceutical is 7.9x.
What is the current FCF of Yixintang Pharmaceutical?Yixintang Pharmaceutical's last 12 months FCF is $203M.
What is Yixintang Pharmaceutical's FCF margin?Yixintang Pharmaceutical's last 12 months FCF margin is 8%.
What is the current EV/FCF multiple of Yixintang Pharmaceutical?Current FCF multiple of Yixintang Pharmaceutical is 5.1x.
How many companies Yixintang Pharmaceutical has acquired to date?As of May 2026, Yixintang Pharmaceutical has acquired 1 company.
What was the largest acquisition by Yixintang Pharmaceutical?$27M acquisition of Yixintang Simile on 17th May 2022 was the largest M&A Yixintang Pharmaceutical has done to date.
What companies Yixintang Pharmaceutical acquired?Yixintang Pharmaceutical acquired Yixintang Simile.
In how many companies Yixintang Pharmaceutical has invested to date?Yixintang Pharmaceutical hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Yixintang Pharmaceutical

Lists including Yixintang Pharmaceutical

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial